Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Omiganan 1% Gel in Preventing Local Catheter Site Infections/Colonization in Patients Undergoing Central Venous Catheterization

NCT00231153 is registered in ClinicalTrials.gov with Cadence Pharmaceuticals as lead sponsor.

NCT NCT00231153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00231153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Omiganan 1% Gel in Preventing Local Catheter Site Infections/Colonization in Patients Undergoing Central Venous Catheterization
Lead sponsor
Cadence Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2005
Completion date
July 31, 2008
Enrollment
1,859 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

infection